Redeye interviewed Neola Medical's CEO, Hanna Sjöström, following the company's Q2 2026 report.
SinterCast bekräftar vändningen i volymerna under H1, men vi sänker årets volymantagande 10 procent.
Redeye comments on the recent newsflow in Biovica.
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
BICO's Q2 marked a second consecutive quarter of positive organic growth, alongside a return to EBIT...
Redeye provides a research update following the Q2 report recently published by ExpreS2ion.
SynAct Pharma reported Q226 operating expenses of SEK24.
Q2 contained few surprises, and the small absolute figures remain of limited importance to our estim...
Redeye expected higher sales in Q2 and consequently stronger earnings.
* Sales of SEK 89m (+17% vs. ABGSCe 76m), a 63% y-o-y growth * Order book at a record at SEK ~640m *...
Redeye provides an initial take on the Q2 2026 report from Cheffelo, published this morning.
SMAG is a rare pure-play on the mobile communications infrastructure behind the digital battlefield.
Q2 sales grew 18.1% yoy to € 25.4m, marking the second strong quarter this year.
Catella's second quarter was a stable print against a low bar.
Steyr Motors' profit warning was not entirely unexpected following a weak Q1 and the absence of mean...
Agtira levererade sitt starkaste kvartal hittills, med en omsättningsökning på 118 procent och posit...
Investors House reported Q2 revenues of EUR 1.4m, 3% below our estimate.
SUS delivered a strong Q2, beating expectations on both sales and EBIT.
* Volumes strong, sales up 10% y-o-y * Adj. EBIT growth of 8% y-o-y, margin of 21% * DOCS now penetr...
Cantargia completed the rights issue in Q2, bringing in SEK75m before costs and entering into a loan...
